<DOC>
	<DOC>NCT02371967</DOC>
	<brief_summary>Previous clinical trials have demonstrated the efficacy of Erivedge速 in patients with advanced Basal Cell Carcinoma (BCC) and Gorlin syndrome. This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of Erivedge速 and to assess actual day-to-day disease and patient management by the physician.</brief_summary>
	<brief_title>An Observational Study of the Effectiveness and Safety of Erivedge速 in Patients With Advanced Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<criteria>Age &gt; / = 18 years at time of study enrollment BCC that meets one of the study's prespecified cohort definitions Physician's decision to treat patient with Erivedge速 as per local label Has not participated in a clinical trial within 90 days prior to study enrollment, with the exception of patients who meet the criteria for Cohort 2 Female patients are excluded if they are pregnant or if they plan to become pregnant during treatment or within 2 years after end of treatment Male patients with female partners of childbearing potential are excluded if they plan to impregnate their partner during treatment or within 2 months after end of treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>